Multi-Omics Market Set for Explosive Growth to USD 33.25 Billion by 2033, Led by North America's 48.8% Market Share | Key Players - BD, Thermo Fisher Scientific Inc., Illumina, Inc.

The Global Multi omics Market reached USD 3.25 Billion in 2024 and is expected to reach USD 33.25 Billion by 2033, growing at a CAGR of 26.1% during the forecast period 2025-2033.

Market growth is driven by surging demand for integrated biological data analysis, rising applications in precision medicine and drug discovery, and advancements in high-throughput sequencing technologies. Expanding use in oncology, genomics-driven personalized therapies, increasing R&D investments by pharma giants, and growing partnerships between biotech firms and AI platforms are further accelerating market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/multiomics-market?ram

Key Industry Developments

United States:
✅ January 2026: Illumina launched its advanced 5-base multiomics sequencing solution, enabling deeper integration of genomics, proteomics, and metabolomics data for precision medicine applications, significantly improving resolution in cancer profiling and personalized therapies.

✅ December 2025: Thermo Fisher Scientific introduced an upgraded multiomics platform integrating single-cell RNA-seq with proteomics, enhancing disease understanding and drug development workflows.

✅ October 2025: Dante Genomics expanded Dante Omics AI into the U.S., revolutionizing multiomics data integration for healthcare and agricultural precision breeding programs.

Asia Pacific / Japan:
✅ November 2025: Takeda Pharmaceutical integrated multiomics into its oncology programs, combining genomics and proteomics for patient-specific therapies, with applications extending to AgTech crop protection.

✅ September 2025: Sony Group Corporation initiated a research partnership with Japanese institutions to develop AI-multiomics tools for biomarker discovery in agriculture and medicine.

✅ August 2025: Kao Corporation unveiled a multiomics-based platform for biotech R&D, targeting sustainable AgTech solutions like microbiome-enhanced fertilizers.

Strategic Mergers and Acquisitions:
✅ Bruker expanded its multiomics capabilities in June 2025 by acquiring Austria-based Biocrates, a leader in mass spectrometry-based quantitative metabolomics, enhancing clinical research tools.

✅ Illumina advanced its proteomics strategy in June 2025 with the announced $350 million acquisition of SomaLogic, integrating aptamer-based technology to boost multiomics biomarker discovery and market growth.

✅ Lucius Partners' portfolio company PD Theranostics merged with Ovation in September 2024 (leading into 2025 activities) to form a leading multiomics data platform, supporting personalized medicine integration.

Key Players:
BD (Becton, Dickinson, and Company) | Thermo Fisher Scientific Inc. | Illumina, Inc. | Danaher Corporation | Bruker Corporation | QIAGEN N.V. | Agilent Technologies, Inc. | Genedata | Shimadzu Corporation | Element Biosciences

Strategic Leadership Report: Top 5 Players in Multi-Omics Market 2026
-Thermo Fisher Scientific Inc.: Launched the Multi-Omics Data Analysis software integrated with LC-MS workflows, enabling seamless integration of proteomics, metabolomics, and genomics data for accelerated biomarker discovery in precision medicine.

-Illumina, Inc.: Introduced the NovaSeq X Plus sequencer with multi-omics expansion kits, supporting high-throughput single-cell and spatial transcriptomics alongside epigenomics to uncover complex disease mechanisms.

-Danaher Corporation: Advanced the Beckman Coulter Life Sciences multi-omics platforms via Sciex acquisition synergies, featuring triple quadrupole mass specs for integrated proteomics-lipidomics workflows that enhance drug development pipelines.

-Bruker Corporation: Released the timsTOF Ultra mass spectrometer for 4D multi-omics profiling, combining ion mobility separation with proteomics and metabolomics for unprecedented depth in microbiome and cancer research.

-QIAGEN N.V.: Expanded the QIAcuity digital PCR system with multi-omics sample prep kits, facilitating integrated NGS and epigenetics analysis for liquid biopsy applications in early cancer detection.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=multiomics-market?ram

Market Drivers and Key Trends:
-Precision Medicine Surge: Multi-omics integration enables personalized therapies by combining genomics, proteomics, and metabolomics data for tailored treatments in oncology and rare diseases.

-Drug Discovery Acceleration: Holistic molecular profiling uncovers novel biomarkers and pathways, streamlining target identification and reducing development timelines for biopharma.

-Chronic Disease Research: Rising demand for integrative biology insights drives adoption in studying complex conditions like cancer, diabetes, and neurodegeneration.

-Technological Advancements: Falling sequencing costs and AI-driven data analytics enhance scalability of multi-omics workflows.

-Market Hurdles: Data integration complexities, high computational demands, and interoperability challenges limit broader clinical translation.

Regional Insights:
-North America: 48.8% (Largest share, driven by advanced biotech infrastructure and high R&D investments in the U.S.).

-Asia Pacific: 28% (Fastest growing, fueled by rapid biotech expansion in China, India, and Japan).

-Europe: 23% (Supported by strong research funding and precision medicine initiatives in Germany and the U.K.).

Market Opportunities & Challenges: Multi-Omics Market 2026
-Opportunities: A "Precision Medicine Surge" propels single-cell multi-omics adoption, with the integrated datasets segment eyeing a 26.1% CAGR through 2033. AI-driven bioinformatics subsidies and Asia-Pacific's genomic infrastructure boom led by China and India's R&D investments-enable de-risked scaling for pharma-biotech consortia.

-Challenges: Data harmonization bottlenecks from siloed omics platforms inflate analysis costs by 20-30%, while stringent GDPR/HIPAA evolutions demand "Federated Learning" compliance. Fragmented bulk vs. single-cell workflows hinder scalability amid talent shortages in computational biology.

-Strategic Verdict: High-margin AI-multi-omics platforms and oncology biomarker pipelines fuel 2026 dominance, prioritizing North America-Asia partnerships.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/multiomics-market?ram

Market Segmentation Analysis:
-By Technology: NGS Dominates with Data Depth
Next-generation sequencing (NGS) leads at 45% share in 2024, enabling high-throughput genome analysis for integrated omics insights.
Mass spectrometry follows at 25%, excelling in proteomics and metabolomics quantification via precise molecular identification.
Microarrays hold 20%, valued for affordable gene expression profiling in early research.
Other techniques like PCR and chromatography claim 10%, supporting targeted validation in multi-omics workflows.

-By Product & Service: Instruments Command Largest Share
Instruments capture 40% market share, powering core data generation in labs for genomics and proteomics.
Reagents & consumables follow at 30%, essential for routine high-volume assays across omics platforms.
Software & services take 20%, aiding data integration and bioinformatics analysis.
Kits & assays account for 10%, offering standardized, user-friendly solutions for specific multi-omics applications.

-By Application: Oncology Leads Amid Precision Medicine
Oncology holds 35% share, driven by tumor profiling for personalized therapies via integrated genomics and proteomics.
Drug discovery & development follows at 25%, accelerating target identification through multi-omics screening.
Personalized medicine claims 20%, tailoring treatments via patient-specific omics data.
Others, including diagnostics and agriculture, split 20%, expanding in biomarker discovery and functional studies.

-By End-User: Pharma & Biotech Prevails in R&D
Pharma & biotechnology firms dominate at 50% share, investing heavily in multi-omics for drug pipelines and biomarkers.
Academic & research institutes follow at 25%, advancing foundational multi-omics studies.
CROs hold 15%, providing outsourced sequencing and analysis services.
Clinical labs & hospitals take 10%, applying omics in diagnostics.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.